Fort Sheridan Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Fort Sheridan Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$512K	Hold	1,701	–	–	0.06%	191
2026 Q1	$563K	Hold	1,701	–	–	0.07%	175
2025 Q4	$676K	Hold	1,701	–	–	0.09%	138
2025 Q3	$776K	Hold	1,701	–	–	0.1%	127
2025 Q2	$555K	Hold	1,701	–	–	0.08%	146
2025 Q1	$459K	Hold	1,701	–	–	0.07%	165
2024 Q4	$400K	Sell	1,701 -32	-2%	-$8.42K	0.06%	180
2024 Q3	$477K	Hold	1,733	–	–	0.07%	155
2024 Q2	$421K	Buy	+1,733	New	+$274K	0.07%	165
2024 Q1	–	Sell	-1,078	Closed	-$206K	–	207
2023 Q4	$206K	Buy	+1,078	New	+$184K	0.04%	187
2023 Q3	–	Sell	-1,078	Closed	-$205K	–	196
2023 Q2	$205K	Hold	1,078	–	–	0.05%	188
2023 Q1	$216K	Buy	+1,078	New	+$227K	0.05%	179

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fort Sheridan Advisors's ALNY Position: Q2 2026 in Review

Fort Sheridan Advisors held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 1,701 shares worth $512K. The position accounts for 0.06% of the portfolio, ranked #191.

Fort Sheridan Advisors first reported a position in ALNY in Q1 2023 and has held it in 12 quarters since. The position peaked at $776K in Q3 2025. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Fort Sheridan Advisors held 1,701 shares of Alnylam Pharmaceuticals worth $512K as of Q2 2026.
Fort Sheridan Advisors left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
Alnylam Pharmaceuticals made up 0.06% of Fort Sheridan Advisors's portfolio in Q2 2026, its #191 holding.
Fort Sheridan Advisors first reported a position in Alnylam Pharmaceuticals in Q1 2023 and has held it in 12 quarters since.
Fort Sheridan Advisors's Alnylam Pharmaceuticals position peaked at $776K in Q3 2025.
785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Fort Sheridan Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.